Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Comment by narmacon Nov 16, 2021 9:52am
152 Views
Post# 34131252

RE:RE:RE:RE:RE:RE:Still Waiting for 1st Dosed Patient

RE:RE:RE:RE:RE:RE:Still Waiting for 1st Dosed Patient,,,On another point for diluting and this next financing is the possiblity that our team of business professionals want to lower HLs ownership percentage by issuing a significant # of shares to a new insider. At this level around .40 cents one could expect maybe100 million shares to be added to our share structure. Our team do have expenses!! I can see insider tensions existing these past two years,,,,,Lebioda probably left under stress! ,,,no sign of updates to his Linkedin profile as of this date. The excitement in Calgary might be due to stress and not the science,,,,anyway our team is probably playing crib and surfing the net,,reading these reviews and laughing,,,,,all the way to the bank!!!,,,what work is going on behind the scene seems to be by third parties!!.......great work if you can get it!!!! jmo
<< Previous
Bullboard Posts
Next >>